Michelle Green

发表

An early cost analysis of magnetic bone growth stimulation in England

M. Bhandari, S. Harper, S. Sprague, 2021, Expert review of pharmacoeconomics & outcomes research.

Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England.

A. Goette, G. Boriani, B. Wilkoff, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England

Michelle Green, J. Shore, A. Hardy, 2020, Expert review of pharmacoeconomics & outcomes research.

Cost‐effectiveness of a cardiac contractility modulation device in heart failure with normal QRS duration

D. Burkhoff, M. Cowie, G. Hasenfuss, 2019, ESC heart failure.

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

E. Antman, R. Giugliano, S. Zhou, 2012, Thrombosis and Haemostasis.

Cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in low surgical risk aortic stenosis patients.

M. Lettino, P. Vandoni, G. Pesarini, 2022, International journal of cardiology.

Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France.

G. de Pouvourville, B. Iung, M. Gilard, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery

H. Kastrissios, S. Rohatagi, J. Mendell, 2012, Thrombosis and Haemostasis.

Model‐Supported Development of CS‐8635: A Fixed‐Dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide

Raymond Miller, Helen Moore, S. Rohatagi, 2013, Clinical pharmacology in drug development.

Cost-effectiveness of SAPIEN 3 transcatheter aortic valve implantation in low surgical mortality risk patients in Spain

P. Candolfi, Bruno García del Blanco, J. Luis Zamorano, 2022, REC: interventional cardiology (English Edition).

Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups

James G. Wright, Diansong Zhou, T. Riccobene, 2018, Clinical and translational science.

An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK

L. Frankenstein, P. Candolfi, J. Russell, 2020, Journal of medical economics.

Cost-Effectiveness of SAPIEN 3 Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in German Severe Aortic Stenosis Patients at Low Surgical Mortality Risk

K. Kuck, L. Frankenstein, R. Leidl, 2023, Advances in Therapy.

Cost-utility analysis of TAVI compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in the Netherlands

P. Harst, W. Oortwijn, P. Tonino, 2024, Cost effectiveness and resource allocation : C/E.